Tezspire’s positive Phase 3 eosinophilic esophagitis data open a new growth avenue for the asthma biologic
Executive summary: Tezspire met co-primary and secondary endpoints in a 52‑week Phase 3 trial for eosinophilic esophagitis, showing statistically and clinically meaningful improvement vs placebo. Adds a new indication to an already approved biologic, potentially expanding its addressable market and offering a novel therapeutic option for an underserved patient population.
Who is involved: Amgen and GSK (co‑developers of Tezspire), trial investigators, patients with eosinophilic esophagitis.
Likely next: Companies will prepare regulatory submissions to FDA and EMA, with potential approval sought in late 2026 or early 2027.
The Phase 3 data confirm that tezepelumab’s mechanism of thymic stromal lymphopoietin inhibition translates to histologic and symptomatic benefit in eosinophilic esophagitis. This expands the drug’s utility beyond severe asthma, where it is already approved, and positions it as a potential first‑in‑class biologic for an eosinophilic‑driven GI disorder. The result reduces reliance on off‑label steroids or dietary elimination and could shift treatment algorithms. However, regulatory filing and reimbursement negotiations remain pending before commercial impact materializes.
Timeline
- — TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS (PR Newswire)
Analysis — what this means
Likely next events
- FDA advisory committee meeting on Tezspire for EoE expected Q1 2027
- Amgen/GSK may submit BLA supplement to FDA by Q4 2026
- AbbVie anticipates EMA decision on Skyrizi subcutaneous Crohn's by mid‑2027
Sectors affected
- eosinophilic esophagitis therapeutics
- biologics for inflammatory diseases
- asthma biologic market
Regulatory implications
- Positive Phase 3 may support priority review designation from FDA for Tezspire in EoE
- EMA may consider accelerated assessment for AbbVie's Skyrizi subcutaneous indication
Historical parallels
- Dupilumab (Dupixent) received FDA approval for eosinophilic esophagitis in May 2022
- Mepolizumab approval for severe asthma in 2015 expanded eosinophilic disease treatment landscape
Key entities
Sources
Open the full interactive case file on Beyond →